Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Effects of immunomodulating therapy in systemic sclerosis.

F H van den Hoogen1, A M Boerbooms, L B van de Putte

  • 1Department of Rheumatology, University Hospital Nijmegen, The Netherlands.

Clinical Rheumatology
|September 1, 1990
PubMed
Summary

Immunomodulating therapies show potential benefits for systemic sclerosis, but more controlled studies are needed. Current evidence from uncontrolled trials suggests antimetabolites, cyclosporine, and interferon-gamma may help manage this condition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Comment on: Álvarez B, Montero Á, Aramburu F, Calvo E, Ángel de la Casa M, Valero J, et al. Radiotherapy for ostheoarticular degenerative disorders: When nothing else works. Osteoarthritis and Cartilage Open. 2019:100016.

Osteoarthritis and cartilage open·2022
Same author

How should worsening in osteoarthritis be defined? Development and initial validation of preliminary criteria for clinical worsening in knee and hip osteoarthritis.

Scandinavian journal of rheumatology·2017
Same author

Association between serum levels of the proinflammatory protein S100A8/A9 and clinical and structural characteristics of patients with established knee, hip, and hand osteoarthritis.

Scandinavian journal of rheumatology·2014
Same author

An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.

Annals of the rheumatic diseases·2008
Same author

The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells.

Arthritis and rheumatism·2005
Same author

[The anti-synthetase syndrome: muscle disease and multisystem disorder at the same time].

Nederlands tijdschrift voor geneeskunde·2003

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacology

Background:

  • Systemic sclerosis is a complex autoimmune disease characterized by fibrosis and vascular abnormalities.
  • Current treatment strategies often focus on symptom management, with limited options for disease modification.

Purpose of the Study:

  • To review existing literature on immunomodulating therapies for systemic sclerosis.
  • To assess the current evidence for the efficacy of various immunomodulatory agents.

Main Methods:

  • Systematic review of published studies.
  • Analysis of uncontrolled trials and case reports concerning immunomodulating agents.

Main Results:

  • Several immunomodulating agents, including antimetabolites (azathioprine, 5-fluorouracil, methotrexate), cyclosporine, and interferon-gamma, show preliminary positive effects.

Related Experiment Videos

  • The majority of available studies are uncontrolled, limiting definitive conclusions on efficacy.

    • Conclusions:

    • Immunomodulating therapies present a potential avenue for treating systemic sclerosis.
    • High-quality, controlled clinical trials are essential to establish the definitive efficacy and safety of these agents in systemic sclerosis management.